Looks like MD Anderson is the trial site.

Kevetrin Mono therapy.

TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO

There is absolutely not 1 person Shorting CTIX.

There can't be anybody that stupid in this world. Can there?

That's 2 phase 3 trials which Prurisol will NOT require......1 trial 300 patients MAX!

Just 50/81 62% PASI75 in P 2B 300mg and Otezla is HISTORY!
P Superior results.
P Way less side effects
P 12 week dosing VS 16 weeks.

TIC TOC KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO!!

hate to hound you guys but do we need all 189 patients for interim 6 week data?

with the 505 we won't need more than 300 for phase3!!!!

352 Phase2
https://clinicaltrials.gov/ct2/show/NCT00773734?term=otezla+phase2+psoriasis&rank=5

Boodog looks like that pinch alert turned in to a slap alert...

The safety profile of abacavir allowed the 505...sheeeeeesh

9 sites

or be on top of your investment.

Leo PR'd locations 24 and 25 would be active by the weekend of 12/17.
As of yesterday they were still not recruiting according to clinicaltrials.org and now they are recruiting.
So those 2 locations changed....

Those 2 locations were added and recruiting 6 weeks ago.
Database is always behind....

Placebo effect is funny isn't it?
Otezla placebo for Psoriasis is 5%-6%...Otezla 30mg 30-35%
Otezla Placebo for Psoriatic Arthritis is 20%...Otezla 30mg 40% Hmmm only 2 to 1 and still got FDA approval.

Placebo numbers are small when Psoriasis is severe. Wonder how many severe Patients are in the Prurisol trial:)

You don't know Dr. Steve??????

Hate to HOUND you guys but do we need all 189 patients for 6 week interim data?

2 cents septmike..you said over $1.00

and March is gonna twice as nice!
In like a Lion out Like a Lion!

TIC TOC.............

KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!

The SHORTS gave it their best................

Now it's Prurisol,UP and OM's turn.
February is gonna be a good month for longs.
Cohort "B" UP ends
36th Patient for OM done dosing. FABULOUS Results shortly after
Prurisol very visible and outstanding 6 week results leak out like wild fire from all 25 sites!!!!

TIC TOC.

KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!!!

Scotty Otezla only sells for $22,000.
I think Trump might have a problem with Leo selling Prurisol for $200M.
He's trying to keep drug prices down:)

3 clinical sites for 6 patients....tic toc....
KABOOOOOOOOOOOOOOOOOOOOM!

13 weeks of P patient enrollment completed....TIC TOC
KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO!!!

The clinical trials speak for Leo.

Why asap?

Cabel email Leo and let us all know...tia

My favorite line..............................

Meeting 2017 Milestones Sets the Stage to Potentially Initiate 5 Registration Studies in 2018!

Probably a lunch date with Mako...

NO way is he selling the company at this point. Simply out of the question.
Arthur is manning the deal hotline though.

When was the last time Leo put out an after Hours Rockin' PR?
I'd LOVE to see one!!!!

One day closer to

KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!

Otezla commercial states " PASI75 was seen in SOME patients after 16 weeks"

WEAK!

Oh really?

JHawker it's as simple as that!!!

KarinCa you don't have to call it a lock....

BUT I WILL!!!......SHHHEEEEEEEEEESH[color=red][/color]...Just for you thumbdowngreen

George that's not "clear"...:):):):):)

B-OM is a lock. NO question about it.
Twist things how ever you want. UP is Running because OM works....SHEEEEESH!

JHawker that sounds clear to me!

So does interim 6 week data mean all 189 patients complete the 6 weeks or just a partial need to complete 6 weeks? I think it's all 189 patients. What do you think Hound?

Scotty you lucked out a friendly poster emailed me this...

Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
BEVERLY, MA--(Marketwired - August 03, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the selection and addition of two clinical sites to be joining the Company's ongoing Phase 2 clinical trial of Brilacidin-OM for the treatment and prevention of oral mucositis in patients with head and neck cancer. Cellceutix expects recruitment to commence in the coming weeks at the centers, bringing the total number of clinical sites in the study to date to five.
Increasing patient access to the trial is important in the Company's efforts to discover an effective, safe therapy for oral mucositis and also to prove the anti-inflammatory properties of Brilacidin in a clinical setting. Laboratory studies have shown Brilacidin to have antibacterial and anti-inflammatory properties. Two successfully completed Phase 2 clinical trials of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) have demonstrated Brilacidin's ability to rapidly destroy bacteria.
"We are already confident in Brilacidin's anti-infective properties and believe it will be a true breakthrough if Brilacidin works as an anti-inflammatory as well," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "This trial has many implications because, as large as the anti-infective market is, the anti-inflammatory market potential for Brilacidin is even greater. I think it is important for shareholders to understand this and the potential value it brings to the Company. As we collect and analyze data from this trial, it will provide direction in our goal to initiate trials addressing the anti-inflammatory markets. Overall, I am very pleased and excited by what I have seen to date in all of our clinical trials and look forward to providing shareholders with a more comprehensive update upon receipt of additional data from all the participating vendors and clinical sites."

DUH Thus the UP trial!!!!!